Glaser, Dee Anna
Hebert, Adelaide A.
Nast, Alexander
Werschler, William P.
Green, Lawrence
Mamelok, Richard D.
Quiring, John
Drew, Janice
Pariser, David M.
Article History
First Online: 20 May 2019
Compliance with Ethical Standards
:
: This study was sponsored and funded by Dermira, Inc.
: Dee Anna Glaser is an investigator for Allergan, Galderma, ATACAMA, Brickell Biotech, Inc., Dermira, Inc., Evolus, and Sienna Biopharmaceuticals, Inc. and a consultant for Dermira, Inc. William P. Werschler is a consultant and investigator for Dermira, Inc. Adelaide A. Herbert is a consultant for Dermira, Inc. and an employee of the UTHealth McGovern Medical School, which received compensation from Dermira, Inc. for study participation. Alexander Nast is an employee of Charité – Universitätsmedizin Berlin, which received compensation from Dermira, Inc. for study participation; he was an advisory board member for Boehringer Ingelheim, carried out educational activities for Bayer and Novartis, and received research grants from Eli Lilly and Company, Pfizer, GSK, Plc., and MEDA. Lawrence Green is an investigator for Brickell Biotech, Inc. and an advisory board member and investigator for Dermira, Inc. Richard D. Mamelok is a consultant for Dermira, Inc. John Quiring is an employee of QST Consultations. Janice Drew is an employee of Dermira, Inc. David M. Pariser is a consultant and investigator for Brickell Biotech, Inc., Celgene Corporation, Dermira, Inc., LEO Pharma US, Novartis Pharmaceuticals, Promius Pharmaceuticals, Regeneron, and Valeant Pharmaceuticals International, a consultant for ATACAMA, Biofrontera AG, DUSA Pharmaceuticals, Inc., Sonofi, TDM SurgiTech, Inc., and TheraVida, and an investigator for Abbott Laboratories, Amgen, Asana Biosciences, Dermavant Sciences, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Ortho Dermatologics, Peplin Inc., Pfizer Inc., Photocure ASA, and Stiefel (as GSK company).
: The ARIDO open-label extension study was conducted in the USA and Germany. The trial protocol and informed consent forms were approved by local institutional review boards or independent ethics committees on 10 August, 2015, and the first patient was enrolled on 27 August, 2015. The trial was registered on ClinicalTrials.gov on 18 September, 2015 (NCT02553798) and was carried out in accordance with Good Clinical Practice and the Declaration of Helsinki.